Telix Pharmaceuticals Ltd has released a press release.
FDA Approves Telix Prostate Cancer Imaging Product Illuccix
Filed with ASX ·
Watch Telix Pharmaceuticals' latest callTelix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20Read the transcript of Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call6ix hasn’t read this filing yet.
Telix Pharmaceuticals Limited on 6ix
Earlier from Telix Pharmaceuticals
- Illuccix EU Regulatory Submission Progress Update
- NUCLIBER - Distribution Agreement for Illuccix in Spain
- Illuccix Granted Use Authorisation in Brazil
- Investor Presentation - November 2021
- Australian TGA Approves Illuccix for Prostate Cancer Imaging
Later from Telix Pharmaceuticals
- Targeted Alpha Therapy for Bladder Cancer 1st patient dosed
- Telix completes $175M placement and launches $25M SPP
- Capital Raise Presentation
- Appendix 4C and Activities Report for December 2021 Quarter
- 1st Patient Dosed ProstACT Prostate Cancer Therapy Program
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals